Kiniksa Pharmaceuticals International (KNSA) Cost of Revenue (2021 - 2026)

Kiniksa Pharmaceuticals International has reported Cost of Revenue for 6 years, with the latest figure at $20.8 million in Q1 2026.

• For the quarter ending Q1 2026, Cost of Revenue rose 16.39% year-over-year to $20.8 million; the trailing twelve-month figure through Mar 2026 stood at $80.6 million (up 18.19% YoY), and the FY2025 full-year result was $77.7 million, up 27.52% from the prior year.
• Cost of Revenue for Q1 2026 stood at $20.8 million, down from $20.9 million in the prior quarter.
• The five-year high for Cost of Revenue was $20.9 million in Q4 2025, with the low at $491000.0 in Q1 2023.
• Historically, Cost of Revenue has averaged $12.3 million across 5 years, with a median of $10.6 million in 2024.
• Annual changes were most pronounced in 2023 — Cost of Revenue sank 88.36% — and 2024, when it soared 2055.4%.
• Kiniksa Pharmaceuticals International's Cost of Revenue stood at $6.7 million in 2022, then surged by 42.83% to $9.6 million in 2023, then jumped by 86.73% to $17.9 million in 2024, then grew by 17.04% to $20.9 million in 2025, then declined by 0.71% to $20.8 million in 2026.
• The last three Cost of Revenue figures came in at $20.8 million (Q1 2026), $20.9 million (Q4 2025), and $20.3 million (Q3 2025), per Business Quant data.